Sarcopenia in Singapore — the silent loss of muscle that changes everything after 60

Most people don’t notice sarcopenia until something breaks. A misstep that should have been a stumble becomes a fall. A bag of groceries feels heavier than it used to. A grandchild becomes harder to lift. By the time these moments register, the underlying process — the gradual, quiet loss of skeletal muscle mass and function with age — has typically been progressing for a decade or more.

Sarcopenia is one of the strongest independent predictors of falls, fractures, hospitalisation, loss of independence, and all-cause mortality in adults over 60. And unlike most conditions that warrant clinical attention at midlife, it produces almost no symptoms in its early stages.

This is why measuring it matters. At Advantage Medical Group, the VITAL Longevity Screen (from SGD 2,588, available at our Bukit Timah clinic) includes a proper sarcopenia assessment — a DEXA scan that measures muscle mass directly, a grip strength test, a walking pace test, a treadmill VO₂ max, and the hormonal blood markers that influence how well your body holds onto muscle. None of this is part of a standard health screen in Singapore, including the Ministry of Health’s Screen for Life programme.

This article explains what sarcopenia is, why the complications matter long before the symptoms appear, and what a proper diagnostic assessment looks like.

What sarcopenia actually is

For most of medical history, losing muscle with age was just called getting older. That changed in the late 1980s, when researchers noticed the rate of loss varied widely between people the same age — and that the difference predicted who fell, who broke a hip, who recovered from surgery.

The condition got a name — sarcopenia — and over the next thirty years, formal diagnostic criteria. Today, sarcopenia is recognised as a disease in its own right, with three components doctors look for:

• Low muscle strength — how forcefully you can grip, lift, or rise from a chair
• Low muscle mass — how much skeletal muscle you actually have, measured most accurately by DEXA
• Low physical performance — how well your body translates strength into useful function, like walking speed

Here’s the part that matters for screening: these three things don’t decline at the same time.

Strength goes first. Mass follows. Visible function — like walking more slowly than you used to — comes last. Which means by the time someone notices they’re slower, the underlying changes have already been happening for years. The window for the most useful interventions sits earlier, before any of this becomes obvious.

This is why a sarcopenia assessment doesn’t wait for symptoms. The point is to catch the trajectory while it’s still easy to change.

The complications, before the symptoms

This is the part of the picture that explains why we screen for sarcopenia in patients who feel fine. The complications come well before the symptoms — and most of them, by the time they arrive, are hard to take back.

A fall that breaks something. People with sarcopenia fall about twice as often as their peers, and when they fall, they’re far more likely to break a bone. Hip fractures in particular are not minor events: roughly one in five people who fracture a hip dies within a year, and that number has barely shifted in thirty years of medicine. Bone density gets all the headlines. The muscle that catches you on the way down — and absorbs the impact when bone meets floor — gets none.

A hospital admission that leads to even more muscle loss. When someone with sarcopenia is admitted to hospital for any reason — pneumonia, an infection, surgery — they tend to stay longer, recover slower, and end up back in hospital sooner than other patients the same age. Bed rest accelerates the problem: a week of lying still can cost about a kilogram of muscle, and at older ages, that loss is genuinely hard to rebuild. Many patients leave hospital functionally weaker than they arrived.

Loss of independence. There’s a measured walking pace — about 0.8 metres per second, which is roughly a comfortable stroll — that doctors use as a marker for whether someone is likely to remain independent over the next few years. Slower than that, and the probability of needing help with daily activities (bathing, dressing, getting out of a chair) climbs sharply. Most people don’t notice when they cross this line. Their family does.

A metabolic shift that hides in plain sight. Muscle is the body’s main destination for the sugar in your bloodstream after a meal. Less muscle means less storage, which means more sugar floating around — the early signature of insulin resistance, often years before standard glucose tests pick anything up. Sarcopenia and type 2 diabetes feed each other; once both are present, neither responds as well to treatment as it would have alone.

A mortality signal that holds up across studies. Across large cohort studies, people with sarcopenia have a 30–60% higher rate of dying from any cause over the following decade than people the same age without it — independent of weight, BMI, and standard cardiovascular risk markers. The signal holds across countries, ethnicities, and definitions. It’s one of the more consistent findings in geriatric medicine.

Why standard screens miss it

In Singapore, the Ministry of Health’s Screen for Life programme is designed to detect chronic diseases — diabetes, hypertension, hyperlipidaemia, and certain cancers — at a population level. It does not assess muscle mass, muscle strength, or physical function. Most private health screens in Singapore follow the same pattern: blood tests, a chest X-ray, an ECG, sometimes an ultrasound, and a doctor’s review.

None of those tests detect sarcopenia.

The reasons are partly historical. Sarcopenia was only formally classified as a disease in the past decade, and the diagnostic protocols are recent. Many primary care templates pre-date this work. There is also a measurement issue: a thorough sarcopenia assessment requires equipment — DEXA, hand-grip dynamometer, sometimes a calibrated walkway — that most general practices do not have on site.

This means that in standard care, sarcopenia is typically diagnosed only after a sentinel event: a fall, a fracture, an unexpected weight loss, or a hospital admission that exposes the underlying weakness. By that point, the goal shifts from prevention to mitigation — and the available interventions, while still worth doing, work less powerfully than they would have ten years earlier.

The case of sarcopenic obesity

There is a particular version of this problem that deserves attention on its own, because it is consistently missed. It’s called sarcopenic obesity: the combination of low muscle and high body fat, often in someone whose weight on the scale looks completely normal.

Imagine a 60-year-old woman, 70 kg, BMI of 24. By every standard measure, she is a healthy weight. Her annual screen comes back unremarkable. Her clothes fit. Her doctor doesn’t mention anything. But underneath, her body has been quietly redistributing — less muscle than she had at 45, more fat, more of it concentrated around her organs. The total weight is the same. The contents are not.

She has higher cardiovascular risk than her BMI suggests. She has worse insulin sensitivity than her glucose readings reveal. She is at higher risk of falls and fractures than her appearance implies. And none of the tools used in standard screening will detect any of this. BMI cannot. Bathroom scales cannot. Even a careful clinical examination will usually miss it.

The reason this pattern matters more now than it would have thirty years ago is that the body composition of the average adult has shifted. People today, on average, carry less muscle and more fat at any given weight than adults of the same age and weight in the 1980s. The number on the scale has not changed. What’s underneath has.

DEXA is the test that sees it. It separates total body weight into bone, fat, and muscle — and tells you not just how much muscle you have, but where it is and what proportion of your body it makes up. It’s the difference between a number and a picture.

We’ll cover the metabolic side of this story in more depth — particularly its overlap with insulin resistance — in a companion article in this series.

What drives muscle loss after 50

A few things change in midlife that conspire to make muscle harder to keep. The useful thing about understanding them is that each one is testable, and most of them are addressable.

Your body gets worse at hearing protein

When a 30-year-old eats a piece of grilled chicken, their muscles register the protein and start building. Same chicken, same person at 55, smaller response. Same chicken at 70, smaller still.

This is sometimes called anabolic resistance, and it has a practical implication: older adults need more protein per meal to get the same muscle-building signal that a younger person gets from less. Roughly a third more, and spread across the day rather than concentrated in dinner.

Most people over 50 do not eat anywhere near this much protein, and most have never been told they should.

Hormones that helped you build muscle stop showing up

Testosterone in men starts dropping from the early thirties and falls more steeply after 40. Oestrogen in women drops sharply during perimenopause. IGF-1 and growth hormone — the body’s main signals for muscle growth and repair — follow similar curves.

These are all testable in a blood sample, and they’re part of what the VITAL Screen measures. Knowing where you sit on these curves changes the clinical picture: if hormones are part of why someone is losing muscle faster than expected, that’s something to factor into the plan.

To be clear: this is not an argument for hormone replacement. Whether to consider testosterone therapy in men, or hormone therapy in perimenopausal women, depends on a much wider clinical conversation — symptoms, risk factors, contraindications, what the person actually wants. A blood marker on its own doesn’t trigger a prescription. But not measuring the markers means working blind.

Background inflammation, slowly turned up

As people age, a low-grade inflammatory signal tends to creep up — not the kind that makes you feel sick, but the kind that shows up on blood tests like hsCRP. It accelerates muscle loss, and the upstream causes are mostly fixable: visceral fat, poor sleep, untreated insulin resistance, sedentary days, even untreated gum disease — but only if measured.

The cells doing the work get tired

At a deeper level, the energy machinery inside muscle cells gets less efficient and nerve connections to the muscle get fewer. There’s no direct test for this in primary care, but the effects show up clearly in grip strength, walking speed, and VO₂ max — when those numbers move, something underneath is changing.

Walking is good. It is not enough.

Of all the drivers above, the one with the biggest evidence base for reversal is mechanical loading — making muscles work against resistance, regularly, for years. Most adults over 50 don’t do this. Even those who exercise regularly often spend almost all their time on walking, running, or cycling — which are great for the heart but don’t load muscle hard enough to preserve it after midlife.

This is the most common pattern we see: a patient who considers themselves active, with a respectable step count, who has not lifted anything heavy in twenty years and does not realise that this is the gap.

What a proper assessment measures

A clinical sarcopenia assessment combines three categories of measurement: muscle quantity, muscle strength, and physical performance.

The first three items in this table are the core sarcopenia diagnostic. The remaining items provide the context — the why behind any abnormal finding. A clinical assessment that measures only the first three tells you whether sarcopenia is present. A clinical assessment that measures all six tells you what to do about it.

The VITAL Longevity Screen at AMG includes all of these, alongside the cardiovascular and metabolic markers that overlap with sarcopenia risk. A comprehensive assessment takes a single morning at our Bukit Timah clinic, with results reviewed in a 60-minute physician consultation.

What you do with the result

Most patients we screen for sarcopenia fall into one of three patterns. The pattern matters because it changes what’s worth doing next.

Pattern one: the body is doing fine. A 56-year-old who has lifted weights twice a week for years walks in. Her DEXA shows muscle mass at the high end for her age. Grip strength is strong. She moves through the chair-rise test without thinking about it. There is nothing to fix.

What changes for her is small but useful. We confirm her protein intake is in a good range — typically around 1.2–1.6 grams per kilogram of body weight per day, more on training days. We agree to repeat the screen in two or three years to track the trajectory. The point of the assessment was to know, not to intervene, and now she does.

Pattern two: something is starting to slip. A 62-year-old man, active in his thirties and forties, less so in his fifties. Cardio fitness has held up. But the DEXA shows muscle mass at the lower end of normal, his grip is below where it should be for his build, and his walking speed is fine — for now.

This is where the largest opportunity sits. The plan is concrete: structured resistance training twice weekly minimum, focused on movements that load the body meaningfully — squats, deadlifts, presses, rows, scaled to him. Protein redistributed across his three meals rather than packed into dinner. We test his testosterone, hsCRP, and HOMA-IR; if any are contributing, we factor them in. Six months later, the change is usually visible on a repeat assessment.

What’s reversible at 62 is harder to reverse at 72.

Pattern three: it has already happened. A 74-year-old who falls once, recovers, and comes in because his daughter pushed him to. His muscle mass is well below the threshold. Grip is weak. His walking speed has slowed without him noticing. He is still independent, but the margin is thinner than he or his family realised.

The interventions are largely the same — resistance training, protein, addressing reversible drivers — and they still work, even into the eighties. But the slope of recovery is shallower, and the more pressing job is preventing the next fall, the next admission, the loss of the independence he still has. This is the kind of patient where the clinical priority is to hold the line, and where the value of having a baseline becomes obvious in retrospect: if we’d seen him at 64, we’d be having a different conversation.

In every one of these patterns, the heavy lifting is done by training and protein, not medicines. There are circumstances where medication helps — clinically significant testosterone deficiency, untreated diabetes — but those are responses to specific findings, not the general answer. The general answer is boring: load the muscles, feed them properly, do it for years.

Why we measure this at AMG

Most patients we see who have eventually had a sarcopenia-related event — a fall, a hip fracture, a hospital admission that took something they didn’t get back — had a standard medical record that looked unremarkable in the years before. Their cholesterol was treated. Their blood pressure was treated. Their BMI was fine. The thing that mattered most for their next twenty years was simply never measured.

That’s the gap longevity screening exists to close.

The clinical logic is the same one we apply to Lp(a), insulin resistance, and the rest of what the VITAL Screen measures: by the time standard tools detect the problem, the most useful interventions are harder to apply. A first DEXA, grip strength, and walking pace at 50 gives you a baseline — a starting line. The repeats at 53, 56, and 59 turn that baseline into a trajectory. The trajectory is what tells you whether you’re on a path that needs changing.

For most people, the assessment will be reassuring. They’ll see a body that’s holding up, get specific targets for keeping it that way, and come back in a couple of years to check. For others — usually fewer than they expect — it’ll catch something earlier than they would have caught it otherwise. Both outcomes are useful. Both are part of why we do this.

The cost of measuring is low. The cost of not knowing, or only knowing too late, is the part that most cannot afford.